Vimta Labs Ltd Performance
Open
481.1
Traded Value (Cr)
55.34 L
Prev. Close
482.9
VWAP
487.7
Volume
11,498
Face Value
2
Vimta Labs Ltd Fundamentals
Vimta Labs Ltd Financials
Resistance and Support
₹500.05
PIVOT
Resistance | |
---|---|
First Resistance | ₹510.450 |
Second Resistance | ₹525.350 |
Third Resistance | ₹535.750 |
Support | |
---|---|
First Resistance | ₹485.150 |
Second Resistance | ₹474.750 |
Third Resistance | ₹459.850 |
RSI | 56.735 |
MACD | 24.481 |
ADX | 36.371 |
CCI | -26.821 |
Delivery and Volume
About Vimta Labs Ltd
Vimta Labs Ltd., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc. The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994. In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia. During 2002, the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials. The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park, Genome Valley, Turkapally Village, Shamirpet Mandal, Ranga Reddy Dist. The project is expected to commence from September 2005. During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006. During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company.
Managing Director
Harita Vasireddi
Founded
1990
NSE Symbol
VIMTALABS
Vimta Labs Ltd Management
Name | Designation |
---|---|
S P Vasireddi | Executive Chairman |
V Harriman | Director (Operation) |
Harita Vasireddi | Managing Director |
Y Prameela Rani | Non-Exec. & Independent Dir. |
Sujani Vasireddi | Company Sec. & Compli. Officer |
G Purnachandra Rao | Non-Exec. & Independent Dir. |
Sanjay Dave | Non-Exec. & Independent Dir. |
Satya Sreenivas Neerukonda | Executive Director |
Yadagiri R Pendri | Non-Exec. & Independent Dir. |
Vimta Labs Ltd News
Similar Stocks
Company | Market Cap | Market Price | P/E Ratio |
---|---|---|---|
CDSL | ₹ 21,652 Cr | ₹ 2,072.00 (-4.46 %) | 59.59 |
GODREJAGRO | ₹ 10,665 Cr | ₹ 554.90 (-5.20 %) | 29.87 |
RTNINDIA | ₹ 9,682 Cr | ₹ 70.05 (-3.11 %) | 20.25 |
THOMASCOOK | ₹ 9,378 Cr | ₹ 199.30 (-4.85 %) | 115.64 |
CMSINFO | ₹ 6,495 Cr | ₹ 399.10 (-1.43 %) | 20.31 |